Aptevo Therapeutics Inc.
Developing multi-specific antibody immunotherapies for hematologic and solid tumor cancers.
APVO | NDAQ
Overview
Corporate Details
- ISIN(s):
- US03835L2079
- LEI:
- Country:
- United States of America
- Address:
- 2401 4TH AVE., 98121 SEATTLE
- Website:
- https://aptevotherapeutics.com/
- Sector:
- Manufacturing
- Industry:
- Manufacture of pharmaceuticals, medicinal chemical and botanical products
Description
Aptevo Therapeutics Inc. is a clinical-stage biotechnology company focused on developing novel immunotherapies for cancer treatment. The company utilizes its proprietary ADAPTIR™ platform to create bispecific and trispecific antibody candidates designed to engage the patient's immune system to combat disease. Its pipeline targets various hematologic malignancies and solid tumors. The lead candidate, Mipletamig, is a CD3 T-cell engager targeting the CD123 tumor antigen for the treatment of Acute Myeloid Leukemia (AML). Other programs in development target antigens such as 5T4, PSMA, and Nectin-4 for various solid tumors, including prostate cancer.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| No filings match the current criteria. | |||||
Automate Your Workflow. Get a real-time feed of all Aptevo Therapeutics Inc. filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Aptevo Therapeutics Inc.
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Aptevo Therapeutics Inc. via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
